Effect of Nebivolol on Microalbuminuria in Hypertensive Patients with or without Type 2 Diabetes Mellitus

Abstract

Objective: To evaluate the effect of nebivolol on microalbuminuria (MA) in hypertensive patients with or without type 2 diabetes mellitus.Materials and Methods: This was an open-label, prospective study. Drug naive patients with stage I hypertension with or without type 2 DM with MA (urine albumin: creatinine ratio [UACR] between 30–300 mg/g) were enrolled in the study and were started on nebivolol 5 mg orally once daily. Efficacy parameters UACR, blood pressure (BP) were measured at baseline and 24 weeks. Paired t-test was used to analyze efficacy endpoints. P < 0.05 was considered to be statistically significant.Results: A total of 30 participants completed the study. Participants who received nebivolol showed a significant decrease in mean UACR, systolic BP, and diastolic BP at 24 weeks compared to baseline (P < 0.001). No participant discontinued the study because of adverse events.Conclusion: Nebivolol has a favorable effect on MA in addition to its antihypertensive effect in hypertensive patients. Further studies with large samples are required to characterize this effect of nebivolol on clinical outcomes.

Keywords: Endothelial dysfunction; hyperglycemia; mean arterial blood pressure; oxidative stress; proteinuria